Gadoterate meglumine (Synonyms: Gd-DOTA; Magnescope) |
Catalog No.GC26684
One-Click Copy Product Info
|
Gadoterate meglumine is a non-specific paramagnetic gadolinium complex used as a contrast-enhancing agent in magnetic resonance imaging (MRI).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 92943-93-6
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Gadoterate meglumine is a non-specific paramagnetic gadolinium complex used as a contrast-enhancing agent in magnetic resonance imaging (MRI). Gadoterate meglumine enhances the signal intensity of MRI images by shortening the longitudinal relaxation time (T1) of tissues. Gadoterate meglumine can be used for imaging the central nervous system (e.g., brain and spinal cord), abdominal and pelvic organs, as well as for angiography and cardiac electrophysiology studies[1-2].
References:
[1] Jordan VC, Sojoodi M, Shroff S, et al. Molecular magnetic resonance imaging of liver inflammation using an oxidatively activated probe. JHEP Rep. 2023 Jul 18;5(10):100850.
[2] Shahid I, Morvan J, Darmon-Kern E, et al. Safety of Gadoterate Meglumine: A Review of 35 Years of Clinical Use and More Than 170 Million Doses. Invest Radiol. 2025 Nov 1;60(11):711-721.
Method for the Application of Gadoterate Meglumine in Mouse Kidney Magnetic Resonance Imaging (MRI)
This protocol is adapted from research data and provided for reference only. Adjustments may be necessary based on specific experimental requirements.
(1) Experimental Animal Model: Unilateral kidney ischemia-reperfusion injury (IRI) mouse model.
(2) Imaging Probe Preparation: The longitudinal relaxivity (r₁) of Gadoterate meglumine (Gd-DOTA) as an MRI probe is 2.8/(mM·s) under a 4.7T magnetic field. Gadoterate meglumine is prepared as a 50mM aqueous solution before use.
(3) MRI Imaging Protocol: Mice undergo MRI scanning via a tail vein catheter under isoflurane anesthesia. A 4.7T small-bore MRI scanner and a custom-built volume coil are used. Gadoterate meglumine is administered intravenously at a dose of 0.025mmol/kg. Dynamic imaging is performed using a high-resolution 2D T1-weighted FLASH sequence (acquisition time: 150 seconds) or a 3D T1-weighted FLASH sequence (acquisition time: 53 seconds) to monitor the kinetic process of renal signal enhancement and washout.
Precautions:
(1) The experimental procedures must comply with animal ethics requirements. During the imaging process, it is essential to ensure stable vital signs in the mice and maintain an appropriate depth of anesthesia.
(2) For your safety and health, please wear a lab coat and disposable gloves during operation.
References:
[1] Rosales IA, Zhou IY, Ay I, et al. Imaging kidney inflammation using an oxidatively activated MRI probe. Kidney Int. 2024 Oct;106(4):671-678.
| Cas No. | 92943-93-6 | SDF | |
| Synonyms | Gd-DOTA; Magnescope | ||
| Formula | C23H42GdN5O13 | M.Wt | 753.86 |
| Solubility | H2O : ≥ 200 mg/mL (265.30 mM) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.3265 mL | 6.6325 mL | 13.2651 mL |
| 5 mM | 265.3 μL | 1.3265 mL | 2.653 mL |
| 10 mM | 132.7 μL | 663.3 μL | 1.3265 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)